WO1990011758A3 - Utilisation d'un agoniste potassique dans le traitement du glaucome - Google Patents

Utilisation d'un agoniste potassique dans le traitement du glaucome Download PDF

Info

Publication number
WO1990011758A3
WO1990011758A3 PCT/FR1990/000223 FR9000223W WO9011758A3 WO 1990011758 A3 WO1990011758 A3 WO 1990011758A3 FR 9000223 W FR9000223 W FR 9000223W WO 9011758 A3 WO9011758 A3 WO 9011758A3
Authority
WO
WIPO (PCT)
Prior art keywords
potassic
agonist
glaucoma
treatment
chromene
Prior art date
Application number
PCT/FR1990/000223
Other languages
English (en)
Other versions
WO1990011758A2 (fr
Inventor
Patrick Gautier
Fur Gerard Le
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of WO1990011758A2 publication Critical patent/WO1990011758A2/fr
Publication of WO1990011758A3 publication Critical patent/WO1990011758A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

La présente invention a pour objet l'utilisation d'un agoniste potassique pour réduire et/ou contrôler la pression intra-oculaire anormalement élevée. Le cyano-6 (dihydro-1,2 oxo-2 pyridyl-1)-4 diméthyl-2,2 chromène est particulièrement préféré. Ledit agoniste potassique peut, selon l'invention, être utilisé en combinaison avec un agent béta-bloquant adrénergique et/ou avec un anti-inflammoire.
PCT/FR1990/000223 1989-03-30 1990-03-30 Utilisation d'un agoniste potassique dans le traitement du glaucome WO1990011758A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR89/04180 1989-03-30
FR8904180A FR2645021A1 (fr) 1989-03-30 1989-03-30 Utilisation d'un agoniste potassique dans le traitement du glaucome

Publications (2)

Publication Number Publication Date
WO1990011758A2 WO1990011758A2 (fr) 1990-10-18
WO1990011758A3 true WO1990011758A3 (fr) 1990-11-29

Family

ID=9380209

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR1990/000223 WO1990011758A2 (fr) 1989-03-30 1990-03-30 Utilisation d'un agoniste potassique dans le traitement du glaucome

Country Status (4)

Country Link
EP (1) EP0465583A1 (fr)
JP (1) JPH04506208A (fr)
FR (1) FR2645021A1 (fr)
WO (1) WO1990011758A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004532249A (ja) * 2001-05-30 2004-10-21 アルテオン インコーポレイテッド 緑内障ｖｉの治療方法

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2735046A1 (de) * 1976-08-04 1978-02-09 Abbott Lab Verwendung von benzopyranen zur verminderung des intraokularen drucks
DE2810801A1 (de) * 1977-03-14 1978-09-21 Abbott Lab Ester von 1,4-aethano-10-hydroxy-5- oxo-5h- eckige klammer auf 1 eckige klammer zu - benzopyrano- eckige klammer auf 3,4-b eckige klammer zu -pyridin
BE868052A (fr) * 1978-06-12 1978-10-02 Sisa Inc Composition et procede pour le traitement du glaucome
US4348398A (en) * 1980-12-23 1982-09-07 Merck Sharp & Dohme (I.A.) Corp. Quinolinyl ethanolamines
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
EP0296975A1 (fr) * 1987-06-23 1988-12-28 MERCK PATENT GmbH Dérivés du diméthyl-2,2 chromannol-3, procédé d'obtention et compositions pharmaceutiques les contenant
EP0323745A2 (fr) * 1988-01-06 1989-07-12 Beecham Group Plc Préparations pharmaceutiques
WO1989010757A1 (fr) * 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Nouvelle preparation ophtalmique pour le traitement de glaucomes

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2735046A1 (de) * 1976-08-04 1978-02-09 Abbott Lab Verwendung von benzopyranen zur verminderung des intraokularen drucks
DE2810801A1 (de) * 1977-03-14 1978-09-21 Abbott Lab Ester von 1,4-aethano-10-hydroxy-5- oxo-5h- eckige klammer auf 1 eckige klammer zu - benzopyrano- eckige klammer auf 3,4-b eckige klammer zu -pyridin
BE868052A (fr) * 1978-06-12 1978-10-02 Sisa Inc Composition et procede pour le traitement du glaucome
US4348398A (en) * 1980-12-23 1982-09-07 Merck Sharp & Dohme (I.A.) Corp. Quinolinyl ethanolamines
DE3726261A1 (de) * 1986-12-23 1988-07-07 Merck Patent Gmbh Chromanderivate
EP0296975A1 (fr) * 1987-06-23 1988-12-28 MERCK PATENT GmbH Dérivés du diméthyl-2,2 chromannol-3, procédé d'obtention et compositions pharmaceutiques les contenant
EP0323745A2 (fr) * 1988-01-06 1989-07-12 Beecham Group Plc Préparations pharmaceutiques
WO1989010757A1 (fr) * 1988-05-10 1989-11-16 Leo Pharmaceutical Products Ltd. A/S (Løvens Kemis Nouvelle preparation ophtalmique pour le traitement de glaucomes

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Current Eye Research, Vol. 4, No. 4, 1985, IRL Press Limited, (Oxford, GB), J.L. RAE: "The Application of Patch Clamp Methods to Ocular Epithelia", pages 408-420 *
J. Med. Chem., Vol. 29, 1986, American Chemical Society, V.A. ASHWOOD et al.: "Synthesis and Antihypertensive Activity of 4-(Cyclic Amido)-2H-1-Benzopyrans", pages 2194-2201 *
Ophthalmology, Vol. 86, Janvier 1979, F.W. NEWELL et al.: "Nabilone: A Pressure-Reducing Synthetic Benzopyran in Open-Angle Glaucoma", pages 156-160 *
Ophthalmology, Vol. 88, No. 3, Mars 1981, American Academy of Ophthalmology, J.S. TIEDEMAN et al.: "Effect of Synthetic Cannabinoids on Elevated Intraocular Pressure", pages 270-277 *
Pharm. Therap., Vol. 43, No. 1, 1989, Maxwell Pergamon MacMillan Plc, (GB) M.F. SUGRUT: "The Pharmacology of Antiglaucoma Drugs", pages 91-138 *
Therapie, Vol. 44, No. 6, 1989, J.F. GIUDICELLI et al.: "Les Activateurs des Canaux Potassiques: de la Pharmacologie a la Therapeutique", pages 419-430 *
TIPS, Vol. 9, Janvier 1988, Elsevier Publications, (Cambridge, GB), N.S. COOK: "The Pharmacology of Potassium Channels and their Therapeutic Potential", pages 21-28 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9439862B2 (en) 2000-05-10 2016-09-13 Novartis Ag Phospholipid-based powders for drug delivery

Also Published As

Publication number Publication date
JPH04506208A (ja) 1992-10-29
EP0465583A1 (fr) 1992-01-15
FR2645021A1 (fr) 1990-10-05
WO1990011758A2 (fr) 1990-10-18

Similar Documents

Publication Publication Date Title
CA2003247A1 (fr) Vis orthopedique
CA2075058A1 (fr) Melanges d'essence pour vehicule et leur utilisation dans des preparations medicales
AU1387088A (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure
AU3074289A (en) 2,2'-iminobisethanol derivatives as potentiators of the effects of blood pressure reducing agents
CA2189709A1 (fr) Pellicule obtenue par extrusion a partir d'un melange de copolymeres ethyliques
EP0166596A3 (en) Biodegradable amphipathic copolymers
CA2258841A1 (fr) Granules destines a la preparation de compositions a haut pouvoir de desintegration et de dissolution, a teneur elevee en medicament
EP0045617A3 (fr) Composition pharmaceutique
AU7684987A (en) Anti-seizing design for circumferentially continuous piston ring
CA2126752A1 (fr) Benzopyrane et antagonistes apparentes du ltb4
WO1990011758A3 (fr) Utilisation d'un agoniste potassique dans le traitement du glaucome
GR3029992T3 (en) Ophthalmological preparation.
ES2098967T3 (es) Cateter urinario externo.
AU627034B2 (en) Fenamate 1,3,4-thiadiazoles and 1,3,4-oxadiazoles as antiinflammatory agents
CA2099195A1 (fr) Tamponnade de l'humeur vitreuse pour la cavite posterieure de l'oeil humain
DE69116224T2 (de) Behandlung von intraokularem Druck mit einer synergischen Kombination
UA48955C2 (uk) Рідка суміш на основі метазахлорину, спосіб її одержання та спосіб боротьби з небажаною рослинністю
USD311023S (en) Animated alphabet font
USD331419S (en) Font
USD334204S (en) Font of type
AU3706093A (en) Liquid bread improvers
AU3952189A (en) Novel derivatives of 6,11-dihydro-dibenzo (c.f.) (1,2,5) -thiadiazepine 5,5-dioxide, salts therof and appropriate processes for the preparation therof
IE873119L (en) 12-halogenated forskolin derivatives, intermediates and a¹process for the preparation thereof and their use as¹medicaments
EP0886351A4 (fr) Laser a semi-conducteur
USD298475S (en) Safety vest

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

AK Designated states

Kind code of ref document: A3

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1990906254

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1990906254

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1990906254

Country of ref document: EP